#1 Clinical Trials Search in Europe

Corticosteroids, Very Potent (Group Iv)

This article discusses a clinical trial investigating the use of very potent corticosteroids (Group IV) in combination with a new drug called lebrikizumab for treating moderate-to-severe atopic dermatitis in children and teenagers. The study aims to assess the effectiveness and safety of this combination therapy compared to a placebo in young patients aged 6 months to under 18 years.

Table of Contents

What are Corticosteroids, Very Potent (Group IV)?

Corticosteroids, Very Potent (Group IV) are a type of medication used to treat various skin conditions. They belong to the strongest group of topical corticosteroids available and are typically used when other, less potent corticosteroids have not been effective.[1]

These medications work by reducing inflammation, itching, and redness in the skin. They are synthetic versions of hormones that your body naturally produces in the adrenal glands.

Medical Conditions Treated

According to the clinical trial information, Corticosteroids, Very Potent (Group IV) are being studied for the treatment of Atopic Dermatitis, also known as Eczema.[1]

Atopic Dermatitis is a chronic skin condition characterized by:

  • Dry, itchy skin
  • Redness and inflammation
  • Recurring rash
  • Skin thickening (in chronic cases)

How are They Administered?

The clinical trial data indicates that Corticosteroids, Very Potent (Group IV) are administered topically.[1] This means they are applied directly to the skin, usually in the form of creams, ointments, or lotions.

Current Clinical Trial Information

A clinical trial (study number 2022-501476-25-00) is currently being conducted to assess the efficacy and safety of a drug called lebrikizumab when used in combination with topical corticosteroids for treating moderate-to-severe atopic dermatitis in children and adolescents.[1]

The main objective of this trial is to evaluate how well lebrikizumab works when used together with topical corticosteroid treatment, compared to a placebo, in participants with moderate-to-severe atopic dermatitis.[1]

Eligibility Criteria for the Clinical Trial

To participate in this clinical trial, patients must meet certain criteria. Some key inclusion criteria are:

  • Have had Atopic Dermatitis for at least 6 months if younger than 6 years old, or 1 year if older than 6 years
  • Be between 6 months and 18 years old
  • Weigh over 6 kilograms if between 6 months and 6 years old
  • Weigh less than 40 kilograms if between 12 and 18 years old
  • Have a parent or legal guardian able to provide consent and follow study guidelines

Some exclusion criteria include:

  • Recent participation in a similar study or use of certain forbidden treatments
  • Pregnancy or breastfeeding
  • Previous adverse reactions to the study drug or topical treatments
  • Severe or current infections requiring strong antibiotics
  • Certain medical conditions that could affect patient safety
  • Drug or alcohol addiction

It’s important to note that these are just some of the criteria, and a healthcare professional would need to assess full eligibility.[1]

Dosage and Treatment Duration

According to the clinical trial information:

  • The maximum daily dose amount is 1 (unit not specified)
  • The maximum total dose amount is 126 (unit not specified)
  • The maximum treatment period is 18 weeks
It’s important to note that these dosages are specific to the clinical trial and may not reflect standard treatment regimens. Always follow your doctor’s instructions regarding dosage and treatment duration.[1]

Precautions and Considerations

When using Corticosteroids, Very Potent (Group IV), it’s important to be aware of the following:

  1. Potency: These are the strongest topical corticosteroids available. They should be used only as prescribed and for the shortest duration necessary.
  2. Side effects: Prolonged use can lead to skin thinning, stretch marks, or other skin changes. Always inform your doctor of any side effects.
  3. Application: Follow your healthcare provider’s instructions carefully on how and where to apply the medication.
  4. Monitoring: Regular check-ups may be necessary to monitor the effectiveness of the treatment and any potential side effects.
  5. Interactions: Inform your doctor about all medications you’re taking, as there may be interactions with other drugs.
Always consult with your healthcare provider for personalized advice and information about using Corticosteroids, Very Potent (Group IV).[1]

Aspect Details
Study Type Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study
Main Objective Evaluate efficacy of lebrikizumab with topical corticosteroids vs. placebo
Participant Age Range 6 months to <18 years
Condition Studied Moderate-to-Severe Atopic Dermatitis
Corticosteroid Type Very Potent (Group IV), Topical Application
Primary Endpoints IGA score improvement, EASI-75 achievement
Treatment Duration Up to 18 weeks
Key Inclusion Criteria Atopic dermatitis duration, age and weight requirements
Key Exclusion Criteria Recent similar studies, pregnancy, severe infections, drug reactions

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to evaluate the effectiveness of lebrikizumab when used together with topical corticosteroid treatment, compared to a placebo, in young patients with moderate-to-severe atopic dermatitis.
  • Who can participate in this study? Participants must be between 6 months and 18 years old, have had atopic dermatitis for at least 6 months (if younger than 6 years) or 1 year (if older than 6 years), and meet specific weight criteria. They must also have a parent or legal guardian who can provide consent and follow study guidelines.
  • What are the main criteria for exclusion from the study? Participants may be excluded if they have recently been in a similar study, received certain treatments, are pregnant or breastfeeding, have had previous reactions to the study drugs, have severe infections, have certain medical conditions, or have addiction issues.
  • How is the effectiveness of the treatment measured? The study measures effectiveness using two main methods: 1) the percentage of participants achieving an Investigator Global Assessment (IGA) score of 0 or 1 with a reduction of at least 2 points from baseline, and 2) the percentage of participants achieving at least a 75% reduction in their Eczema Area and Severity Index (EASI) score.
  • What type of corticosteroid is being used in this study? The study uses very potent corticosteroids, classified as Group IV. These are topical medications, meaning they are applied directly to the skin.

Ongoing Clinical Trials on Corticosteroids, Very Potent (Group Iv)

  • Study of Lebrikizumab and Topical Corticosteroids for Children and Teens with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Poland Spain

Glossary

  • Atopic Dermatitis: A chronic, itchy skin condition that's also known as eczema. It often appears as a red, itchy rash on the skin.
  • Lebrikizumab: An investigational drug being studied for the treatment of atopic dermatitis.
  • Topical Corticosteroids: Steroid medicines that are applied directly to the skin to reduce inflammation and itching.
  • Placebo: A substance that has no active medical effect, used as a control in testing new drugs.
  • Investigator Global Assessment (IGA): A tool used by researchers to evaluate the overall appearance of a skin condition.
  • Eczema Area and Severity Index (EASI): A tool used to measure the extent and severity of atopic dermatitis.
  • Phase 3 Study: A type of clinical trial that tests the safety and effectiveness of a new treatment using a large group of participants.
  • Efficacy: The ability of a treatment to produce the desired result.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.

References

  1. http://clinicaltrials.eu/trial/study-of-lebrikizumab-and-topical-corticosteroids-for-children-and-teens-with-moderate-to-severe-atopic-dermatitis/